GARDASIL® has been shown to reduce the incidence of pre-cancerous cervical, vulvar, and vaginal lesions, and external genital warts causally related to HPV6/11/16/18. Because of its expected public health benefit on reduction of cervical cancer and other HPV-related diseases, this vaccine has been rapidly implemented in the routine vaccination programs of several countries. It is therefore essential to assess its impact and safety through post-licensure surveillance programs. Here, we present a summary of 16 post-licensure safety and impact studies across 20 countries. These studies address general safety, including autoimmune disorders, long-term effectiveness, and type replacement.
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD / P.Bonanni; C.Cohet; SK.Kjaer; NB.Latham; PH.Lambert; K.Reisinger; RM.Haupt. - In: VACCINE. - ISSN 0264-410X. - STAMPA. - 28:(2010), pp. 4719-4730. [10.1016/j.vaccine.2010.04.070]
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
BONANNI, PAOLO;
2010
Abstract
GARDASIL® has been shown to reduce the incidence of pre-cancerous cervical, vulvar, and vaginal lesions, and external genital warts causally related to HPV6/11/16/18. Because of its expected public health benefit on reduction of cervical cancer and other HPV-related diseases, this vaccine has been rapidly implemented in the routine vaccination programs of several countries. It is therefore essential to assess its impact and safety through post-licensure surveillance programs. Here, we present a summary of 16 post-licensure safety and impact studies across 20 countries. These studies address general safety, including autoimmune disorders, long-term effectiveness, and type replacement.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
